In the May 2008 issue of Journal of Clinical Microbiology, provided an excellent minireview of current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-resistant enterococci. In this article, the authors describe a novel rapid culture-based assay, the 3M BacLite rapid MRSA test, which detects MRSA without the need for macroscopic growth of bacterial colonies, allowing the presence or absence of MRSA to be determined within 5 h. The article states the assay detects ciprofloxacin-resistant MRSA and comments that this may lead to the possibility of the assay not detecting communityacquired MRSA strains, as well as some hospital-acquired MRSA strains, that are sensitive to ciprofloxacin. The authors are correct in their statements but refer to an assay formulation that has not been available since February 2007, when ciprofloxacin was replaced by cefoxitin as a selective agent.The ability of the 3M BacLite rapid MRSA test to detect MRSA strains from a diverse genetic background has been evaluated by von Eiff et al. (4). In an extensive study, more than 700 methicillin-susceptible and methicillin-resistant strains, covering Ͼ90% of all registered European MRSA spa types within the SeqNet network, were tested using the 3M BacLite rapid MRSA test. The study reported that all 513 MRSA strains tested were correctly recognized as methicillin resistant while none of the 211 methicillin-susceptible strains were detected as positive. In an additional study (5), 27 MRSA strains recovered from pigs, which have been reported to cause detection problems in some molecular assays, were correctly detected as positive by the 3M BacLite rapid MRSA test. In addition to these analytical studies, there are an increasing number of studies assessing the performance of this assay with clinical specimens. Our group (3) reported a diagnostic sensitivity of 94.6% and a diagnostic specificity of 96.9% for nasal screening swabs and 95.9% sensitivity and 88.8% specificity for groin screening swabs when the assay was referenced to standard operating procedures at three hospital sites in the United Kingdom. More recently Cohen et al. (1) assessed the performance characteristics of the 3M BacLite rapid MRSA assay for a range of body sites compared to chromagar and a commercial molecular assay and concluded that the BacLite assay's performance, ease of use, and capacity best met the needs of the authors' hospital for rapid MRSA screening.The limitations of traditional diagnostic methods coupled with the increase in antimicrobial resistance means that there is a growing demand among health care providers for rapid microbiological tests to assist patient care and disease control.
Authors' ReplyWe thank Dr. OHara for bringing to attention this important information not available at the time of our initial publication (3). While the previous version of the 3M BacLite rapid MRSA test would fail to detect community-acquired methicillin-resistant Staphylococcus aureus (MRSA) and ciprofloxacin-sensitive ho...